Replies to post #206657 on Biotech Values

[DewDiligence]

Gazyva—Same comment, different venue:

Reuters' saying Gazyva raised 3yr survival from 92% to "only" 94% makes it sound trifling, but it's a 25% reduction in 3yr risk of death. https://t.co/mPbXkGoDl9

— Roy Friedman (@DewDiligence) December 6, 2016